Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Clinical Lymphoma & Myeloma Stories

2012-06-04 02:26:17

SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center today announced a non-exclusive research alliance for pre-clinical and clinical research to continue to understand the role that novel experimental therapies, including Onyx's carfilzomib and oprozomib, can play in the potential treatment of multiple myeloma and lymphoma. The term of the agreement extends for two years. Financial...

2012-06-04 02:24:12

WASHINGTON, June 4, 2012 /PRNewswire-USNewswire/ -- Results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. Multiple myeloma is cancer of the plasma cells, the white blood cells...

2011-12-05 13:20:00

WHITE PLAINS, N.Y., Dec. 5, 2011 /PRNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in San Diego December 10-13, 2011. <font size="2" face="Arial">(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO )</font> New discoveries in immunotherapies, blood cancer stem cells, genomics and molecularly targeted therapies will be among the...

2011-11-14 09:00:00

CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 /PRNewswire/ -- University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar. Approximately 17,000 Americans are diagnosed with glioblastoma every year and only two percent of them...

2011-05-10 06:30:00

CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a Phase I study of REOLYSIN(®) alone in patients with relapsed multiple myeloma. The NCI is sponsoring the trial under its Clinical Trials Agreement with...

2011-04-12 10:40:00

NEW YORK, April 12, 2011 /PRNewswire-USNewswire/ -- The Bone and Cancer Foundation (BCF) provides information for cancer patients who have bone related complications including metastasis and cancer treatment induced bone loss. BCF patient publications cover very timely topics including Vitamin D and new treatment options, and are the only publications available that deal specifically with bone metastasis and cancer treatment induced bone loss. The following patient publications have been...

2010-12-06 14:01:56

Results with Estybon (ON 01910.Na) in Patients with myelodysplastic syndromes; ON 013105 cyclin D1 inhibitor active in models of mantle cell lymphoma NEWTOWN, PA and PRINCETON, NJ Dec. 3, 2010 / PRNewswire-FirstCall / Onconova Therapeutics announces its late-stage anticancer agent, Estybon® (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010. Principal investigators at four...

2010-12-01 09:00:00

NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS(TM). The official launch of MyPRS(TM) will take place at the 52nd Annual American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida on December 4th. As part of the product launch the...

2010-12-01 07:00:00

WHITE PLAINS, N.Y., Dec. 1, 2010 /PRNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in Orlando December 4-7, 2010. Throughout the ASH conference, LLS Vice President of Research Communications Deborah Banker, Ph.D., will be available to comment on any research news to emerge from the meeting. To arrange interviews in advance or during the conference, please contact Andrea...

2010-10-26 12:00:00

NEW YORK, Oct. 26 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. They include: Kenneth Anderson, M.D. Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Kraft Family Professor of Medicine, Harvard Medical School Dr. Anderson of Dana-Farber Cancer Institute and Harvard Medical School holds the title of...